. . . . "Cell Cure may, from time to time, sell some or all of the BioTime shares it receives and will use proceeds from the sale of the shares to fund its development program for OpRegen?? and for the development of other products to treat neurological disorders such as multiple sclerosis and Parkinson's disease." .